Updated: Jul 23
On August 1, 2019, Medvantx shipped ancillary supplies, including syringes, transfer needles, injection needles, alcohol prep pads, gauze sponges, and adhesive bandages with Hemlibra vials for Genentech Patient Foundation patients.
On September 18, 2019, they learned that these ancillary supplies shipped by Medvantx contained injection needles of incorrect length for administration of Hemlibra.
Really? it took you a over a month to figure this out?!?!?
On Monday September 23, 2019, both the National Hemophilia Foundation and the Hemophilia Federation of America will be exchanging emails all week to come up with a joint letter with several questions to send to Genentech expressing "concern" for the hemophilia community.
Let me save you some time in writing that letter, someone wasn’t doing their job and put the wrong sized needles in patients’ monthly shipment. Plain and simple. Just like Bayer wasn’t doing their job last month and mislabeled vials of factor.
Now, does using a different sized needle matter? Yes, it does matter. Smaller needles can reduce pain. In this case, they shipped larger needles so patients will experience increased pain.
With all of the money these pharma companies make, they sure do have a terrible quality control system in place. The FDA should fine pharma for these mistakes. These things should not happen.